Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Tekmira Initiating Phase I/II Clinical Trial in Patients with HCC

Published: Friday, May 30, 2014
Last Updated: Friday, May 30, 2014
Bookmark and Share
Designed to determine the safety, tolerability and clinical benefit of TKM-PLK1.

Tekmira Pharmaceuticals Corporation has announced that they have met all regulatory requirements to initiate a Phase I/II clinical trial of TKM-PLK1 in patients with Hepatocellular Carcinoma (HCC). Tekmira is also conducting a separate Phase I/II clinical trial evaluating TKM-PLK1 in patients with Gastrointestinal Neuroendocrine Tumors (GI-NET) or Adrenocortical Carcinoma (ACC).

"Hepatocellular carcinoma is associated with one of the poorest survival rates in oncology, and clearly new therapies are needed. We are encouraged with the positive data from our GI-NET and ACC clinical studies with TKM-PLK1 and there is sound rational for evaluating this agent in HCC," said Dr. Mark J. Murray, Tekmira's President and CEO.

"We are excited about reaching another important milestone for Tekmira by launching this new clinical trial, and also remain on track to share results from our GI-NET/ACC trial in the second half of this year," added Dr. Murray.

This trial is an open-label, multi-center, Phase I/II dose escalation study in patients with advanced hepatocellular carcinoma. The study is designed to determine the safety, tolerability and clinical benefit of TKM-PLK1. The study will be conducted at sites in North America and Asia.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tekmira Announces Launch of Arbutus Biopharma
Four HBV product candidates advancing in human clinical trials in 1H16.
Friday, July 24, 2015
Tekmira Provides Periodic Update on TKM-Ebola Program
Commences manufacture of new RNAi therapeutic for Ebola - Guinea variant.
Friday, October 31, 2014
Tekmira Joins Ebola International Consortium
Tekmira joins international consortium to conduct clinical trials of Ebola virus therapeutics in West Africa.
Wednesday, September 24, 2014
Tekmira Provides Update on TKM-Ebola Phase I Clinical Hold
All other clinical development programs on track.
Thursday, July 24, 2014
Tekmira Presents Positive Interim Results on Phase I/II Clinical Programs
Confirms safety profile of third generation LNP.
Friday, May 23, 2014
Tekmira Pharmaceuticals TKM-Ebola Clinical Trial Approved
Investigational New Drug (IND) application for TKM-Ebola has been approved by the United States FDA, allowing Tekmira to initiate a Phase 1 clinical trial.
Tuesday, November 29, 2011
Tekmira Pharmaceuticals Announces Multi-Year Agreement with Bristol-Myers Squibb
BMS will use siRNA molecules formulated by Tekmira in stable nucleic acid-lipid particles to silence target genes of interest.
Friday, May 14, 2010
Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial
ApoB SNALP is designed to reduce the production of apolipoprotein B.
Monday, January 11, 2010
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!